UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities

Figures & data

Table 1. Patient demographics.

Patient characteristic
Age, in years, mean ± SD	48.9 ± 15.0
Gender
Female, n (%)	77 (71.3%)
Male, n (%)	31 (28.7%)
Urticaria type
Standalone CSU, n (%)	67 (62.0 %)
CSU & CIndU, n (%)	38 (35.2%)
Isolated AE, n (%)	3 (2.8%)
Duration of dual therapy for CU in months, mean ± SD	24.6 ± 21.3
Duration of triple therapy for CU in months, mean ± SD	4.9 ± 3.2

CSU = chronic spontaneous urticaria, CIndU = chronic inducible urticaria, AE = angioedema; n = 108.

Table 2. Comorbidities of patients.

	n	%
Comorbidity
Hypothyroidism	50	46,3%
Hypertension	47	43,5%
Atopies	27	25,0%
Allergic rhinoconjunctivitis	21	19,4%
Allergic bronchial asthma	10	9,3%
Atopic dermatitis	3	2,8%
Depression	16	14,8%
Sleep disorders	14	13,0%
Dyslipidemia	12	11,1%
Diabetes I and II	12	11,1%
Allergies	12	11,1%
Autoimmune diseases	12	11,1%
Psoriasis	3	2,8%
Ulcerative colitis	2	1,9%
Lupus erythematosus	2	1,9%
Celiac	2	1,9%
Crohn’s disease	1	0,9%
Myasthenia gravis	1	0,9%
Vitiligo	1	0,9%
Subacute cutaneous lupus erythematosus	1	0,9%
Bechterew’s disease	1	0,9%
Family Mediterranean fever	1	0,9%
Chronic pain	9	8,3%
Coronary artery disease	5	4,6%
Malignancies	4	3,7%
Active breast cancer	1	0,9%
State after breast cancer	1	0,9%
Chronic lymphatic leukemia	1	0,9%
Myeloproliferative Syndrome	1	0,9%
Cardiac arrhythmia	4	3,7%
Chronic gastritis	4	3,7%
COPD	4	3,7%
Restless legs-syndrome	3	2,8%
Hyperuricemia	3	2,8%
Iron deficiency	3	2,8%
Anxiety disorder	3	2,8%
Sleep apnea	3	2,8%
Benign prostatic hyperplasia	2	1,9%
Migraine	2	1,9%
Factor- V- Leiden mutation	2	1,9%
Hepatitis C	1	0,9%
Chronic hepatitis B	1	0,9%
Peripheral arterial occlusive disease	1	0,9%
von-Willebrand-syndrome	1	0,9%
Osteoporosis	1	0,9%
Kallmann-syndrome	1	0,9%
Bladder hyperactivity	1	0,9%
Hypoparathyroidism	1	0,9%
Adrenocortical insufficiency	1	0,9%
Thalassemia minor	1	0,9%
Eosinophilic esophagitis	1	0,9%
Endometriosis	1	0,9%
Onychomycosis	1	0,9%
Polycystic ovary syndrome	1	0,9%
Diverticulosis	1	0,9%
Chronic diverticulitis	1	0,9%
Fructose intolerance	1	0,9%
Protein S-deficiency	1	0,9%
Vitamin D-deficiency	1	0,9%
Acid reflux	1	0,9%
Herpes labialis	1	0,9%
Chronic Bronchitis	1	0,9%
Hyperthyroidism	1	0,9%

Table 3. Duration of co-medication of the most frequent comorbidities.

Co-medication	Mean of co-medication duration ± SD next to DT for CU in months, median	95% confidence interval Mean
Co-medication of thyroid dysfunction	22.1 ± 18.5, 16.9	17.0–27.1
Co-medication of hypertension	26.4 ± 23.2, 21.4	20.0–32.8
Co-medication of cardiovascular prophylaxis	25.5 ± 23.8, 15.6	12.8–38.2
Co-medication of dyslipidaemia	17.2 ± 20.1, 7.7	6.1–28.3
Co-medication of diabetes	19.0 ± 22.6, 9.0	5.9–32.0
Co-medication of depression	16.2 ± 15.7, 11.3	9.4–22.9
Co-medication of sleep disorders	6.4 ± 6.8, 3.8	1.2–11.7